[港股招股说明书]：恒瑞医药招股说明书 -尊龙凯时人生就博

" data-src="https://public.fxbaogao.com/report-image/2025/05/15/4839758-1.png?x-oss-process=image/crop,x_0,y_0,w_1980,h_2800/resize,p_60" data-sizes="200px" data-error="fx-img-error-default;;;height: 720px;" data-srcset="https://public.fxbaogao.com/report-image/2025/05/15/4839758-1.png?x-oss-process=image/crop,x_0,y_0,w_1980,h_2800/resize,p_60" class="lazy"/>

江 蘇 恒 瑞 醫 藥 股 份 有 限 公 司jiangsu hengrui pharmaceuticals co., ltd. （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ）股份代號:1276 全 球發 售 jiangsu hengrui pharmaceuticals co., ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2025515 www.hkeipo.hk(2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025520 (3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025520 (a) (b)(4). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025520 fini (3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025520 (5). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025521 www.hengrui.com(6)www.hkexnews.hk . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025522 •www.hengrui.com(6)www.hkexnews.hk. . . . . . . . . . . . . . . . .2025522 2025528 852 3691 8488 . . . . . . . . . . . . . . . 20255232025528 eipo h (7)(9). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025522 (8)(9). . . . . . . . . . . . . . . . . . . . . 2025523 2025523 moaglp-1(i) hrs-7535glp-1(ii) hrs9531glp-1gip(iii) hrs-4729glp-1gipgcgsirna(gene silencing)c3 (apoc3)sirna(agt)sirna (i)il-17a(ii)jak1(iii) shr-1905tslp(iv) shr-1703il-5(v)ifnar1/taci(vi)il-23p19/il-36r ebitda 202220232024d.a 江蘇恒瑞醫藥股份有限公司1997428a600276 ema www.hkeipo.hk eipo fini 1%0.0027%0.00015%0.00565% h h 1%0.0027%0.00565%0.00015% 33,677,800 2022202320241231 5-ht3 api anda adc aoc bid cdk gmp gnrh hba1c hcc her2 hr igg1 nav1.8 protac psma ras rlt rna saa sclc sglt-2 sirna smo spid cfius h 202512 20254 2024 1 health insurance portability and accountability act of 1996hipaa hipaa(health information technology for economic and clinical health act) 2022772022 10% 20091231 [2009]167 [2010]70 h 2006714 h h h 8.1219a.15 8.1219a.15 19a.15 頴 3.101117 (i) 3.282 h 8.5% f15(1) f113(7) ubs am singaporeubs am singaporeubs asset managementubs asset managementubs group agubs group agubs ag hong kong branchubs amubs ag hong kong branchf113(7)ubs amubs ag hong kong branch f15(1) singapore ubs ag hong kong branch (e)ubs am singaporeubs ag hong kong branch4.15 h h h hh h 63101 1998801 88221201 813a – 129 – 20 d-1-101 1910 133 11703 46 46 350 citigroup global markets limited 33 canada squarecanary wharflondon e14 5lbunited kingdom 33 canada squarecanary wharflondon e14 5lbunited kingdom citigroup global markets limited 33 canada squarecanary wharflondon e14 5lbunited kingdom 9962 17172504 191920 頴fcghkfcghkicpa fda pd-(l)1ctla-4pd-(l)1 (i)20182023 2020122202071(2020) 2017317201751201751 iii 20201210 (i)(ii)(iii) 201511 2017320175 2020720207 (gcp)ich 201876 2020730202091 20157 201710 (i) 19981214 1999512 2007710 201613 20002162000718200091 2000772001882009117 201911 2021115 2 0 2 262 0(gy-yd2022-1)202332(gy-yd2023-1)20231013(gy-yd2023-2)2024329(gy-yd2024-1)20241122(gy-yd2024-2) 2020528202111 2018720201911 2018921 20181116 201941 1999432019324 2024118202511 (ii) (1) pd-l1 shr-a1921 (4)(5) 200,000 2011. . . . . . . . . . . . . . . . 2024. . . . . . . . . . . . . . . .kailera therapeuticsideaya biosciences 1997461.9 8.08(1)(b)19a.13a 89.2.8%(ii)25.4t.6%(iii)10�% (1)(6) pd-1pd-l1 adc shr-1707hrg2010 1.8(nav1.8) adcras hrs-4642 dtp h l bl i f e hlb life iiichart 20185 g-csf shr-1707 nav1.8 ideaya biosciences 202412ideayabiosciencesideayabiosciencess h r -4849i d e a y abiosciences75200ideaya biosciencesshr-4849770 kailera therapeutics mrkdg 202310merck healthcare kgaa(mrkdg)(i)mrkdghrs-1167(ii)mrkdgshr-a1904(iii)mrkdghrs-1167shr-a1904 elevar therapeutics dr. reddy’s treeline biosciences 20232treeline biosciences, inc.treeline biosciences treeline biosciencesshr2554ezh2 dong-a st hlb life science 20209hlb life science co., ltd.hlb life science crystalgenomics tg therapeutics arcutis biotherapeutics 20212 pi3kδ 202211 novaliq cldn18.2 adcshr-4849dll3 adc(shr-a1811) hart-igg (asco) 14asco 202311 (ii)(iii)(iv) esgesg 11 covid-19 covid-19 2035104 1231202220232024 (1). . . . . . . . . . . . . . . . . . . . .–24,19365,255(2). . .–2475,097(3). . . . . . . . . . . . . . . .–6631,740. . . . . . . . . . . . . . . . . . . . . . . . . .–25,10372,092(4). . . . . . . . . . . . . . . . . . . . .–13713(5). . .–1363,894. . . . . . . . . . . . . . . . . . . . . . . . . .–2733,907 2022202320241231 20222023202420212022202312311,020.51,019.91,273.820254a202412311,275.5h 3.09d 3.13 gip/glp-1glp-1gip/glp-1 ii. sglt-2dpp-4 3.10(2)3.21 c.2.c.3. 3a.19 3a.23 (ii) invesco advisers ucits invescoivz.ny invesco invesco developing markets fund1940 ubs am singapore ubsamsingapore199312 (i)ubs (lux) equity fund – greater china (usd); (ii) ubs (lux) equity fund – chinaopportunity (usd); (iii) ubs (hk) fund series – china opportunity equity (usd);(iv) u